Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

The purpose of this study is to determine the rate of minimum residual disease (MRD) negative response (i.e. the rate of no evidence of disease) of the study drugs, zanubrutinib, obinutuzumab, and venetoclax, given in combination as a treatment for CLL and/or SLL.

Trial Details

NCT ID
NCT03824483
Phase
PHASE2
Sponsor
Memorial Sloan Kettering Cancer Center
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Zanubrutinib
  • Obinutuzumab
  • Venetoclax
Locations (sample)
  • Evanston, Illinois, United States|42.04114,-87.69006
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Basking Ridge, New Jersey, United States|40.70621,-74.54932
  • Middletown, New Jersey, United States|40.39428,-74.11709
  • Commack, New York, United States|40.84288,-73.29289

Key Eligibility Criteria

  • \- Signed, informed consent
  • Ability and willingness to comply with the requirements of the study protocol
  • Age ≥18 years
  • Diagnosis of the following histories according to the WHO criteria

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →